Skip to main content
Full access
Letter to the Editor
Published Online: 1 June 2000

Parenteral Valproate for Control of Acute Mania

Publication: American Journal of Psychiatry
Valproate is a safe and effective antiepileptic and thymoleptic drug. An intravenous form has been available since December 1996; it is approved for the treatment of complex partial and absence seizures but not for bipolar disorder (package insert, Abbott Laboratories). A recent case report discusses using intravenous valproate for controlling agitation in an 8-year-old autistic patient (1). We are not aware of any literature on its use for mania.
Ms. A was an 81-year-old nursing home resident with a long history of bipolar disorder, including approximately 10 hospitalizations for manic episodes; her condition was maintained with divalproex and haloperidol therapy. She had recently developed Alzheimer’s dementia.
The dementia manifested in growing apathy, with Ms. A often sitting for long periods fully awake but with her eyes closed. It was thought that she was becoming lethargic, and her haloperidol dose was tapered off. This brought no dramatic change, so her divalproex dose was tapered and discontinued. Within a week, Ms. A was euphoric, loud, argumentative, grandiose (“I’m the greatest lion tamer in the Ringling Brothers Circus!”), paranoid, and hallucinating. Soon she refused to take her medications, and a hasty attempt to restart divalproex therapy failed. Finally, she refused all food and fluids, necessitating hospitalization.
Ms. A was admitted to the psychiatric department. Her manic symptoms continued. Attempts to persuade her to take nutrition, fluids, or medications orally failed, and intravenous fluid replacement was begun. Because of her declining nutritional status and persistent agitation, we decided her condition constituted an emergency. With family consent, we began intravenous haloperidol, 1 mg b.i.d. This lessened her agitation but had no effect on her mania or psychosis.
As Ms. A’s nutritional status continued to deteriorate, we decided, again with family consent, to administer valproate intravenously. We began with 125 mg of valproate in 100 cc of 5% dextrose in water, infused over 1 hour every 6 hours, and increased the infusion to 200 mg after the first two doses. After 2 days (nine doses), Ms. A’s mania cleared. She began eating, drinking, and taking her medications, including divalproex, orally. In the few days until discharge, Ms. A exhibited her baseline playful and pleasantly disoriented dementia (“Get me a beer!”), with no evident psychosis, grandiosity, or other indication of mania. The nine intravenous doses brought her serum valproate level to 53 μg/ml, which had historically been therapeutic for her. She experienced no untoward effects. Ms. A was discharged back to her nursing home with the manic episode resolved.
When acute mood stabilization is required, but the oral route is unavailable, parenteral valproate appears to be a safe and effective alternative. Oral and intravenous total daily doses are equivalent (package insert, Abbott Laboratories). The rapid response in this case suggests that a loading effect might be achieved expeditiously with intravenous administration (presumably with diminished gastrointestinal side effects), although aggressive intravenous dosing for routine control of mania would merit further study for safety.

References

1.
Hilty DM, Rodriguez GD, Hales RE: Intravenous valproate for rapid stabilization of agitation in neuropsychiatric disorders (letter). J Neuropsychiatry Clin Neurosci 1998; 10:365–366

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1023 - 1024
PubMed: 10831494

History

Published online: 1 June 2000
Published in print: June 2000

Authors

Affiliations

J. CRAIG NELSON, M.D.
New Haven, Conn.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share